Avalanche Biotechnologies, Inc. (Avalanche) is clinical-stage biotechnology company. The Company is focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company operates through a single segment, being the business of developing and commercializing therapeutics. Avalanche's Ocular BioFactory platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. The Company’s lead product candidate, AVA-101 is used for the treatment of wet age-related macular degeneration (AMD). The Company’s AVA-201 is a next generation anti-VEGF gene therapy product candidate, which is being developed for the prevention of wet AMD. In addition, Avalanche’s AVA-311 is being developed for the treatment of Juvenile X-linked Retinoschisis (XLRS).